scholarly journals MEK is a promising target in the basal subtype of bladder cancer

Oncotarget ◽  
2020 ◽  
Vol 11 (44) ◽  
pp. 3921-3932
Author(s):  
Nathan M. Merrill ◽  
Nathalie M. Vandecan ◽  
Kathleen C. Day ◽  
Phillip L. Palmbos ◽  
Mark L. Day ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Basal Subtype ◽  
Promising Target

Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells

2021 ◽  
Vol 41 (6) ◽  
pp. 2901-2912
Author(s):  
KAZUKI OKUBO ◽  
MAKOTO ISONO ◽  
TAKAKO ASANO ◽  
NINA REßING ◽  
WOLFGANG A. SCHULZ ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Ubiquitin Proteasome System ◽  
Promising Target ◽  
Bladder Cancer Cells ◽  
Ubiquitin Proteasome

scholarly journals Pparg drives luminal differentiation and luminal tumor formation in the urothelium

2021 ◽  
Author(s):  
Tiffany Tate ◽  
Tina Xiang ◽  
Mi Zhou ◽  
William Y. Kim ◽  
Xiao Chen ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Bladder Cancer ◽  
Nuclear Receptor ◽  
Tumor Formation ◽  
The Body ◽  
Luminal Subtype ◽  
Basal Subtype ◽  
Luminal Tumor ◽  
Muscle Invasive ◽  
Treatment And Diagnosis

AbstractPparg, a nuclear receptor, is downregulated in basal subtype bladder cancers that tend to be muscle invasive and amplified in luminal subtype bladder cancers that tend to be non-muscle invasive. Bladder cancers derive from the urothelium, one of the most quiescent epithelia in the body which is composed of basal, intermediate, and superficial cells. We find that expression of an activated form of Pparg (VP16;Pparg) in basal progenitors induces formation of superficial cells in situ, that exit the cell cycle, and do not form tumors. Expression in basal progenitors that have been activated by mild injury however, results in luminal tumor formation. We find that tumors are immune deserted, which may be linked to downregulation of Nf-kb, a Pparg target. Interestingly, some luminal tumors begin to shift to basal subtype tumors with time, downregulating Pparg and other luminal markers. Our findings have important implications for treatment and diagnosis bladder cancer.

scholarly journals ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A

2021 ◽  
Vol 12 (7) ◽  
Author(s):  
Yuchen Wang ◽  
Jie Wu ◽  
Wenjie Luo ◽  
Hailiang Zhang ◽  
Guohai Shi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Malignant Tumors ◽  
Direct Interaction ◽  
In Vivo Experiments ◽  
Tumor Promotor ◽  
Promising Target ◽  
Bladder Cancer Cells

AbstractBladder cancer is one of the most common malignant tumors in the urinary system. The development and improvement of treatment efficiency require the deepening of the understanding of its molecular mechanism. This study investigated the role of ALPK2, which is rarely studied in malignant tumors, in the development of bladder cancer. Our results showed the upregulation of ALPK2 in bladder cancer, and data mining of TCGA database showed the association between ALPK2 and pathological parameters of patients with bladder cancer. In vitro and in vivo experiments demonstrated that knockdown of ALPK2 could inhibit bladder cancer development through regulating cell proliferation, cell apoptosis, and cell migration. Additionally, DEPDC1A is identified as a potential downstream of ALPK2 with direct interaction, whose overexpression/downregulation can inhibit/promote the malignant behavioral of bladder cancer cells. Moreover, the overexpression of DEPDC1A can rescue the inhibitory effects of ALPK2 knockdown on bladder cancer. In conclusion, ALPK2 exerts a cancer-promoting role in the development of bladder cancer by regulating DEPDC1A, which may become a promising target to improve the treatment strategy of bladder cancer.

288 Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?

2016 ◽  
Vol 15 (3) ◽  
pp. e288
Author(s):  
A. Masson-Lecomte ◽  
N. Sirab ◽  
A. De Reyniès ◽  
P. Maillé ◽  
P. Soyeux-Porte ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Basal Subtype

scholarly journals miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer

2020 ◽  
Vol Volume 12 ◽  
pp. 11805-11816 ◽  
Author(s):  
Zhonglin Cai ◽  
Fa Zhang ◽  
Weijie Chen ◽  
Jianzhong Zhang ◽  
Hongjun Li
Keyword(s):  
Bladder Cancer ◽  
Promising Target

scholarly journals Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells

PLoS ONE ◽  
2020 ◽  
Vol 15 (8) ◽  
pp. e0237976 ◽  
Author(s):  
Aaron A. Mehus ◽  
Nicholas Bergum ◽  
Peter Knutson ◽  
Swojani Shrestha ◽  
Xu Dong Zhou ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Bladder Cancer ◽  
Basal Subtype

A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 519-519 ◽  
Author(s):  
Woonyoung Choi ◽  
Elizabeth R. Plimack ◽  
Arlene O. Siefker-Radtke ◽  
Colin P.N. Dinney ◽  
David James McConkey
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Molecular Subtypes ◽  
Molecular Subtype ◽  
Muscle Invasive Bladder Cancer ◽  
Basal Subtype ◽  
Transcriptome Expression ◽  
Muscle Invasive ◽  
Whole Transcriptome ◽  
Response To Neoadjuvant Chemotherapy

519 Background: The bladder cancer basal and luminal molecular subtypes have been associated with differential progression patterns and responses to neoadjuvant chemotherapy. However, they are typically identified by whole transcriptome expression profiling, which may be impractical for most academic centers. To make subtype classification more accessible, we developed a 50-gene basal and luminal subtype classifier and examined its performance in matched tumor specimens, including pretreatment biopsies from patients treated with neoadjuvant chemotherapy. Methods: We refined a 50-gene subtype classifier derived from a oneNN classifier containing >~2000 genes that we previously developed using unsupervised methods. We compared its accuracy against calls made using the original oneNN classifier, including 148 tumors from a neoadjuvant chemotherapy meta dataset. To test subtype stability, tumors in 2 different datasets (30 sets of matched primary and lymph node tumors and 43 sets of matched pre- and post-chemotherapy tumors) were assigned using 50-gene subtype classifier with Linear Discriminator Analysis (LDA) prediction algorithms. Results: In the NAC cohort, patients with tumors assigned to the basal subtype by the 50-gene classifier had better survival outcomes compared to the luminal tumors, consistent with the conclusion generated with the parent classifier (p<0.05). Basal subtype assignments were stable in 62.5 % of pairs, whereas luminal tumors displayed 100% stability. In matched pre- and post-chemotherapy tumors, basal tumors displayed 78% stability while luminal tumors showed 94% stability. Conclusions: Based on these preliminary data, it appears that basal tumors display higher plasticity than luminal tumors with these specific contexts. This plasticity may interfere with precise subtype predictions with tumors assigned to the basal subtype at biopsy.

Sign in / Sign up

Export Citation Format

Share Document